Published in Am J Gastroenterol on July 01, 2002
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis (2011) 2.12
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse (2010) 1.48
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut (2005) 1.34
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut (2003) 1.11
Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol (2005) 0.95
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials (2013) 0.85
Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection. Saudi J Gastroenterol (2011) 0.84
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Focus on: Alcohol and the liver. Alcohol Res Health (2010) 0.80
Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci (2005) 0.77
Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol (2005) 0.76
The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol (2011) 0.75
Alcohol consumption in patients with primary sclerosing cholangitis. World J Gastroenterol (2012) 0.75
A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. J Ultrasound (2014) 0.75
Primary biliary cirrhosis. Hepatology (2009) 5.35
Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol (2006) 3.57
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int (2009) 3.12
Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology (2004) 2.49
Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med (2011) 2.44
Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology (2002) 2.38
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology (2008) 2.36
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int (2008) 2.19
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut (2012) 2.17
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology (2007) 1.96
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med (2010) 1.94
Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology (2012) 1.92
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology (2005) 1.90
Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol (2005) 1.88
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology (2005) 1.85
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol (2011) 1.82
Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology (2008) 1.73
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol (2010) 1.70
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology (2005) 1.67
Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Arch (2012) 1.63
Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol (2002) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology (2007) 1.58
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest (2003) 1.57
Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology (2002) 1.56
Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol (2008) 1.56
Prognostic scores for cirrhotic patients admitted to an intensive care unit: which consequences for liver transplantation? Clin Res Hepatol Gastroenterol (2013) 1.50
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin? J Hepatol (2009) 1.48
Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int (2009) 1.41
[Liver involvement revealing systemic mastocytosis: report of two cases]. Gastroenterol Clin Biol (2004) 1.40
Need to strictly define hepatitis B virus immunotolerant patients to avoid unnecessary liver biopsy. Gastroenterology (2008) 1.40
Chronic liver injury during obstructive sleep apnea. Hepatology (2005) 1.39
[The liver and pregnancy]. Gastroenterol Clin Biol (2004) 1.39
Pegylated interferon and ribavirin: A therapeutic option in patients who fail to respond to telaprevir-based triple therapy? Hepatology (2013) 1.38
Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology (2007) 1.33
Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer (2006) 1.32
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol (2011) 1.29
Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology (2003) 1.26
Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology (2008) 1.26
PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging (2006) 1.21
Quality of life in patients with primary biliary cirrhosis. Hepatology (2004) 1.20
ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology (2003) 1.18
CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5. Brain (2009) 1.18
Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis (2007) 1.18
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology (2010) 1.14
Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. Hepatology (2015) 1.08
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol (2007) 1.05
Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med (2011) 1.04
Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. Gastroenterology (2011) 1.03
Langerhans' cell histiocytosis of the liver in adults. Clin Res Hepatol Gastroenterol (2011) 1.02
Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol (2010) 1.01
Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology (2013) 0.99
Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol (2008) 0.96
Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol (2006) 0.96
Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study. Eur J Gastroenterol Hepatol (2012) 0.93
Novel mutations in the Dubin-Johnson syndrome gene ABCC2/MRP2 and associated biochemical changes. Ann Clin Biochem (2012) 0.92
Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system. Liver Transpl (2011) 0.91
Vascular involvement of the liver in Turner's syndrome. Hepatology (2004) 0.91
Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol (2002) 0.90
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. Gastroenterol Clin Biol (2005) 0.90
Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol (2004) 0.88
Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology (2009) 0.87
Association between ABO blood group and fibrosis severity in chronic hepatitis C infection. Dig Dis Sci (2006) 0.87
Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology (2003) 0.87
Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol (2011) 0.86
Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine (2002) 0.86
Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology (2004) 0.86